R5XA.F ACELRX PHARMACEUT. DL-01

Healthcare Pharmaceuticals Frankfurt Exchange
0.9350 EUR
Close of Nov 12, 2026
0.6150 1.25
Market cap
EUR 48.5M
P/E
-
P/B
3.82x
ROE
-95.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is R5XA.F undervalued?

Graham number

The Graham number of ACELRX PHARMACEUT. DL-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ACELRX PHARMACEUT. DL-01 fundamental analysis

No fundamental analysis for ACELRX PHARMACEUT. DL-01 yet.

ACELRX PHARMACEUT. DL-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ACELRX PHARMACEUT. DL-01

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory d…

Full company profile